1.Advances in treatment of acute myeloid leukemia in the elderly.
Acta Academiae Medicinae Sinicae 2009;31(5):634-638
Elderly patients with acute myeloid leukemia (AML) tolerate intensive chemotherapy poorly and usually have poor prognosis. For elderly patients in good physical condition and without severe dysfunction of major organs, standard intensive induction chemotherapy is superior to non-intensive treatment or best supportive care alone. However, low-dose chemotherapy as post-remission treatment has more advantages than intensive chemotherapy. Intensive chemotherapy is not suitable for patients with unfavorable karyotypes, and genetic analysis is needed for individualized therapy regimen. Gemtuzumab ozogamicin may improve the survival of elderly patients who are intolerant to standard chemotherapy. Some patients may benefit from the transplantation of allogeneic stem cells after reduced-intensity conditioning.
Aged
;
Humans
;
Leukemia, Myeloid, Acute
;
drug therapy
;
surgery
;
therapy
;
Middle Aged
2.Comparison of total body irradiation-cyclophosphamide versus busulphan-cyclophosphamide as conditioning regimens for myelogenous leukemia: a meta-analysis.
Shi-Xia XU ; Xian-Hua TANG ; Hai-Qing CHEN ; Bo FENG ; Hai-Qin XU ; Xiao-Pei CHEN ; Xiang-Feng TANG
Journal of Experimental Hematology 2008;16(6):1354-1360
Total body irradiation combined with cyclophosphamide (TBI/CY) and busulphan combined with cyclophosphamide (BU/CY) are standard conditioning regimens in hematological stem cell transplantation for patients with myelogenous leukemia. This study was aimed to compare the therapeutic efficacy of TBI/CY and BU/CY as conditioning regiment for acute or chronic myelogenous leukemia. The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, CNKI, CBM (Chinese Bio-medicine Database) had been searched for all relevant articles (1999-2007). Comparative studies were carried out on clinical therapeutic effects of TBI/CY and BU/CY including stem cell engraftment, relapse, complications, transplant-related mortality, and disease-free survival. A meta-analysis was performed using Review Manager 4.2 software and funnel plot regression was adopted to assess the publication bias. The results indicated that 2149 articles in English and 46 articles in Chinese were got, and finally 9 clinical trials with total 3039 patients have been assessed. No significantly difference was found in engraftment failure and transplant-related mortality resulting from TBI/CY and BU/CY conditioning regimens, but the incidence of veno-occlusion of liver and hemorrhagic cystitis obviously increased in BU/CY group after transplantation, the acute GVHD, interstitial pneumonia and cataract significantly increased in TBI/CY group. The relapse rate of AML in TBI/CY group was lower than that in BU/CY group, and the rate of long-term disease-free survival of AML patients in TBI/CY group also significantly lower than that in BU/CY group, but the relapse rate of CML in TBI/CY group after transplantation was obviously higher than that in BU/CY group, but there was no difference in longterm disease-free survival rate between the two conditioning regimens mentioned above. It is concluded that the meta-analysis confirms different effects of TBI/CY and BU/CY regimens on myelogenous leukemia transplantation. This result is useful for physicians to select treatment regimens.
Busulfan
;
therapeutic use
;
Cyclophosphamide
;
therapeutic use
;
Disease-Free Survival
;
Humans
;
Leukemia, Myeloid
;
radiotherapy
;
surgery
;
Leukemia, Myeloid, Acute
;
radiotherapy
;
surgery
;
Transplantation Conditioning
;
methods
;
Treatment Outcome
;
Whole-Body Irradiation
3.Clinical observation of patients with hematologic malignancies treated with hematopoietic stem cell transplantation.
Donghua ZHANG ; Lu ZHANG ; Yi XIAO ; Wei HUANG ; Dengju LI ; Dan RAN ; Liang HUANG ; Jianfeng ZHOU ; Mei HUANG ; Hanying SUN ; Wenli LIU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2004;24(4):345-349
To evaluate the therapeutic effect of hematopoietic stem cell transplantation (HSCT), we performed HSCT in 30 patients with hematologic maligancies. Of the 30 patients, 10 underwent autologous peripheral blood stem cell transplantation (auto-PBSCT), 13 underwent myeloablative allogeneic HSCT while 7 underwent nonmyeloablative allogeneic HSCT, which were designated as autologous group, myeloablative group and nonmyeloablative group, respectively. All patients except the one who underwent cord blood transplantation, were successfully engrafted. Median time for the granulocytes > or = 0.5 x 10(9)/L and platelets > or = 20 x 10(9)/L were 12 days and 13 days respectively in autologous group, 16 days and 19 days in myeloablative group, 15 days and 12 days in nonmyeloablative group. In myeloablative group, acute graft-versus-host diseases (aGVHD) was observed in 3 patients, all of which were I-II grade. Oral mucous cGVHD was observed in 1 patient. In nonmyeloablative group, 1 patient developed intestinal aGVHD grade IV and cutaneous cGVHD was induced by donor lymphocyte infusions (DLI) in 3 patients. 1 patient had hematological relapse in autologous group. 1 patient had cytogenetic relapse in myeloablative group. In nonmyeloablative group 3 patients had cytogenetic relapse and were cured by DLI, 1 patient had hematological relapse. 4 of the 30 patients died of infection (2 patients), grade IV aGVHD (1) and relapse (1) respectively. 26 patients are still alive. 3 years overall survival (OS) and 3 years disease free survival (DFS) were 100% and 64.81% respectively in autologous group, 78.75% and 63% respectively in myeloablative group while both 66.67% in nonmyeloablative group. In conclusion, autologous group had less transplant-related complications and mortality. Active prophylaxis of relapse could significantly promote DFS. The transplant-related mortality limited DFS in myeloablative group. More relapses occurred in nonmyeloablative group, but could be cured by DLI.
Adolescent
;
Adult
;
China
;
epidemiology
;
Female
;
Follow-Up Studies
;
Graft vs Host Disease
;
epidemiology
;
Hematopoietic Stem Cell Transplantation
;
adverse effects
;
Humans
;
Leukemia
;
surgery
;
Leukemia, Myeloid, Acute
;
surgery
;
Leukemia, Myelomonocytic, Chronic
;
surgery
;
Lymphoma
;
surgery
;
Male
;
Middle Aged
4.Renal angiomyolipoma with inferior vena cava and right atrial embolism: A case report and literature review.
Journal of Central South University(Medical Sciences) 2022;47(12):1763-1768
Renal angiomyolipoma (AML) with renal vein, inferior vena cava (IVC), and right atrial embolism is a rare solid tumor, whose etiology and pathogenesis are still unclear. Moreover, it is often misdiagnosed. One patient with renal AML complicated with renal vein, IVC, and right atrial embolism was admitted to the Second Xiangya Hospital of Central South University, who was a 35-year-old female, without any previous medical history, presented with right low back pain for more than 3 years. Computed tomography (CT) scan showed irregular lobulated fatty density mass in the right kidney, renal vein, IVC, and right atrium. The contrast-enhanced scan showed no enhancement of fat components at each phase and mild enhancement of solid components. Radical resection of the right kidney and removal of tumor thrombus were performed, and there was no recurrence 1 year after the operation. It is rare for renal AML to grow along the renal vein, IVC, and extend to the right atrium. Imaging examination is extremely important, and the CT findings of this case are characteristic, but the diagnosis eventually depends on pathological and immunohistochemical examinations.
Female
;
Humans
;
Adult
;
Vena Cava, Inferior/pathology*
;
Angiomyolipoma/surgery*
;
Atrial Fibrillation
;
Kidney Neoplasms/surgery*
;
Embolism/pathology*
;
Heart Atria/diagnostic imaging*
;
Leukemia, Myeloid, Acute/pathology*
5.Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia.
Qian-Lan ZHOU ; Xiao-Wen TANG ; Ai-Ning SUN ; Hui-Ying QIU ; Zheng-Ming JIN ; Miao MIAO ; Zheng-Zheng FU ; Bing-Rui ZHAO ; Xiao-Lan SHI ; Guang-Hua CHEN ; De-Pei WU
Journal of Experimental Hematology 2012;20(4):954-958
The study was aimed to evaluate the impact of disease status on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with refractory and relapsed acute myeloid leukemia (AML). 32 patients with refractory and relapsed AML received allo-HSCT after myeloablative conditioning regimen, including 17 patients in no-remission (NR) and 15 patients in complete remission (CR) at the time of transplant. Treatment related adverse events, relapse rate and leukemia free survival (LFS) were analyzed. The results showed that the parameters of sex, age, cytogenetic risk and transplant procedures were comparable between the two groups. 30 patients had successful engraftment, except one had graft failure and one died from severe veno-occlusive disease in the NR group. The incidences of aGVHD in NR group and CR group were 47.1% (8 patients) and 33.5% (5 patients) respectively. Out of comparable patients, 5 from 9 patients in NR group developed with cGVHD, and 4 from 11 patients in CR group were subjected to cGVHD. There were no statistic difference in incidences of aGVHD and cGVHD between two group. Compa-red with CR group, NR group had a higher treatment-related mortality (29.4% vs 14.3%, P = 0.392) and relapse rate (42.9% vs 26.7% P = 0.300), but there was no significant difference. With a median follow-up of 13 (1 - 124) months, 6 patients remained alive in both of the two groups, and the 2 year LFS of them were parallel (35.3% vs 40.0%, P = 0.267). Among these 32 patients, overall survival (OS) was better in patients with age < 35 years (P = 0.044) and with the appearance of cGVHD (P = 0.046). It is concluded that allo-HSCT is an effective salvage therapy for patients with refractory and relapsed AML, and the overall outcome seems unrelated to the disease status (NR or CR) before transplantation. As such, for refractory and relapsed AML patients in non-remission, performance of allo-HSCT to achieve long-term survival is feasible.
Adolescent
;
Adult
;
Child
;
Female
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Leukemia, Myeloid, Acute
;
diagnosis
;
pathology
;
surgery
;
Male
;
Prognosis
;
Recurrence
;
Salvage Therapy
;
methods
;
Transplantation, Homologous
;
Young Adult
6.Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
Zheng-Ping YU ; Jia-Hua DING ; Bao-An CHEN ; Bi-Cheng LIU ; Hong LIU ; Yu-Feng LI ; Bang-He DING ; Jun QIAN
Chinese Journal of Cancer 2010;29(11):946-951
BACKGROUND AND OBJECTIVEAllogeneic hematopoietic cell transplantation (allo-HSCT) is a potent procedure for the treatment of hematologic diseases, yet it is associated with high risks of treatment-related complications. Except for transplant-related organ toxicities, renal insufficiencies which emerge earlier significantly limit patients' long survival. To analyze risk factors for acute kidney injury (AKI), we conducted a retrospective cohort study of 96 patients undergoing HSCT.
METHODSDuring the first 100 days after allo-HSCT, all patients were evaluated for renal function by measuring serum creatinine clearance and glomerular filtration rate (GFR) with a classification below: Grade 0 (<25%, decline in creatinine clearance), Grade 1 (≥25% decline in creatinine clearance but <2-fold increase in serum creatinine), Grade 2 (≥2-fold rise in serum creatinine but no need for dialysis), and Grade 3 (≥2-fold rise in serum creatinine and need for dialysis). Cox regression model was used to calculate the hazard ratios (HRs) of demographic data, clinical variables, and risk factors for AKI.
RESULTSTwenty-eight (29.2%) patients occurred Grades 1-3 renal dysfunction (Grade 1, 14 patients; Grade 2, 12 patients; Grade 3, 2 patients), and ratios of early kidney injury increased in high-risk malignancy group (HR = 2.945, 95% confidence interval (CI)=1.293-6.421), patients treated with myeloablative conditioning regimen (HR=2.463, 95% CI=1.757-4.320), and patients with acute GVHD (HR=3.553, 95% CI=1.809-6.978), sepsis (HR=3.215, 95% CI=1.189-6.333 ), or hepatic veno-occlusive disease (VOD) (HR=3.487, 95% CI=1.392-6.524). Whereas, HLA histocompatibility showed no striking increased risk for acute renal injury (HR=1.684, 95% CI=0.648-4.378). The survival rate was lower in patients with severe nephrotoxicity (21.4%) than in patients without nephrotoxicity (70.6%) (P=0.001).
CONCLUSIONSNephrotoxicity is the primary risk factor for AKI, severely impacting on survival. Sorts of risk factors mentioned will be useful for evaluation for kidney function of patients undergoing allo-HSCT.
Acute Kidney Injury ; etiology ; Adolescent ; Adult ; Child ; Cohort Studies ; Creatinine ; blood ; Female ; Graft vs Host Disease ; etiology ; Hematopoietic Stem Cell Transplantation ; adverse effects ; Humans ; Kidney Function Tests ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; surgery ; Leukemia, Myeloid, Acute ; surgery ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; surgery ; Proportional Hazards Models ; Recurrence ; Retrospective Studies ; Risk Factors ; Survival Rate ; Transplantation Conditioning ; Transplantation, Homologous ; Young Adult
7.The impact of HLA high resolution typing mismatching of donor-recipient pairs on outcome of unrelated donor hematopoietic stem cell transplantation.
Jun HE ; Chao XU ; Xiao-jin WU ; Xiao-jing BAO ; Qiao-cheng QIU ; Xiao-ni YUAN ; Yang LI ; Hong-jie SHEN ; De-pei WU ; Jun-ling HONG ; Jing-Hu LIU ; Hai-ying DU ; Lei ZHANG ; Dan DU ; Jing LU ; Jing LIU
Chinese Journal of Hematology 2012;33(5):353-357
OBJECTIVETo study the impact of various human leukocyte antigen (HLA) high resolution typing mismatching of donor-recipient pairs on prognosis of unrelated donor hematopoietic stem cell transplantation.
METHODS835 donor-recipient pairs of CMDP data from 2005 to 2010 were analyzed retrospectively. HLA-A, B, C, DRB1 and DQB1 typing were performed using SBT, SSOP and SSP methods. The diseases involved in acute myeloid leukemia (AML) (n = 288), acute lymphoid leukemia (ALL) (n = 227), chronic myeloid leukemia (CML) (n = 187), myelodysplastic syndrome (MDS) (n = 52), non-hodgkin's lymphoma(NHL) (n = 25), aplastic anemia(AA) (n = 42) and thalassemia (n = 14). Of 835 donor-recipient pairs, 362 were completely matched, 159 had a mismatch for a single allele, 125 had a mismatch for a single antigen, 95 had mismatched for both single allele and single antigen, 29 were mismatched at double allele, 20 at double antigen, 45 at multiple allele and antigen. The follow-up assessment was completed before March 2011.
RESULTSHLA-matched pairs had higher overall survival (OS) than HLA-mismatched pairs (79.83% vs 73.15%), but there was no statistically significant differences (P > 0.05). HLA mismatch for a single allele plus a single antigen was a significantly risk factor for OS, disease free survival (DFS) and transplant-related mortality (TRM). The OS from high to low in different diseases were thalassemia, AA, CML, MDS, AML, NHL, and ALL. OS of HLA locus mismatch were DRB1 (94.4%), DQB1 (83.3%), B (75%), A (74.4%) and C (71.4%), respectively. OS of single allele mismatch at HLA locus from high to low were DRB1, C, A, B and DQB1.HLA-A, B, C locus mismatch were statistically significantly associated with lower OS and grade II-IV acute GVHD compared with HLA-matched pairs (P < 0.05). The donor-recipient pairs with HLA-B*15:01/B*15:05, DRB1*12:01/DRB1*12:02, C*04:01/C*03:04, DQB1*03:02/DQB1*03:03 alleles mismatch were given priority. But the donor-recipient pairs with HLA-B*39:01/B*39:05, C*15:02/C*14:02, C*08:01/C*03:04, C*07:02/C*15:02 alleles mismatch were risk factors for influence of OS and aGVHD.
CONCLUSIONThe high resolution typing for HLA-A, B, C, DRB1, DQB1 can be identified nonpermissive mismatch, which is beneficial for the selection of a suitable donor improves survival on unrelated donor HSCT.
HLA Antigens ; genetics ; immunology ; Hematopoietic Stem Cell Transplantation ; Histocompatibility Testing ; Humans ; Leukemia, Myeloid, Acute ; immunology ; surgery ; Lymphoma, Non-Hodgkin ; immunology ; surgery ; Myelodysplastic Syndromes ; immunology ; surgery ; Prognosis ; Retrospective Studies ; Unrelated Donors
8.Allogeneic peripheral blood hematopoietic stem cell transplantation for post-operatively treating acute non-lymphocytic leukemia patient complicated with renal cell carcinoma: one case report.
Hai-Yan ZHU ; Wan-Ming DA ; Chun-Ji GAO ; Xiao-Ping HAN ; Shu-Hong WANG ; Yu JING ; Jian BO ; Hai-jie JIN ; Meng LI
Journal of Experimental Hematology 2008;16(1):203-206
The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic peripheral blood stem cell transplantation (allo-PBHSCT) for post-operative therapy of acute non-lymphocytic leukemia (ANLL) patient complicated with renal cell carcinoma (RCC). One ANLL patient complicated with RCC underwent an myeloablative HLA-identical relative allo-PBHSCT after RCC operation. The conditioning regimen consisted of total body irradiation, cyclophosphamide and cytarabine. Graft versus host disease (GVHD) prophylaxis regimen composed of cyclosporine A, myco-phenolate mofetil and short course of methotrexate. The results indicated that the patient achieved engraftment 16 days after transplantation with full donor-type chimerism detected by STR-PCR at 30 and 100 days after transplantation. No acute or chronic GVHD and any severe complication developed. As of March 2007, the patient remains without disease at follow-up of 44 months. In conclusion, allo-HSCT procedure is feasible and effective for post-operative therapy of ANLL patient complicated with RCC without severe toxicity.
Adult
;
Carcinoma, Renal Cell
;
surgery
;
therapy
;
Graft vs Host Disease
;
prevention & control
;
Humans
;
Kidney Neoplasms
;
surgery
;
therapy
;
Leukemia, Myeloid, Acute
;
therapy
;
Male
;
Neoplasms, Multiple Primary
;
therapy
;
Peripheral Blood Stem Cell Transplantation
;
Postoperative Period
;
Transplantation, Homologous
9.Effect of recombinant human interleukin 11 on the platelet after hematopoietic stem cell transplantation in patients with leukemia.
Ya-jing XU ; Fang-ping CHEN ; Xiao-lin LI ; Xie-lan ZHAO ; Qun HE
Journal of Central South University(Medical Sciences) 2007;32(3):433-436
OBJECTIVE:
To explore the effect and toxicity profile of recombinant human interleukin 11(rhIL-11) on the platelet after hematopoietic stem cell transplantation in patients with leukemia.
METHODS:
Twenty-four patients with acute or chronic leukemia treated by allogeneic peripheral blood stem cell transplantation (PBSCT) were randomly divided into a test group and a control group. The patients in the test group were treated with rhIL-11 since the 13th day after PBSCT (1.5mg/d),while the control group were given symptomatic treatment.
RESULTS:
The average time for the platelet to recover to the level of 20 x 10(9)/L was 20.8 days in the test group, and 26.0 days in control group respectively, there was significant difference (P<0.01). The average time for the platelet to recover to the level of 50 x 10(9)/L was 25.7 days in the test group, and 32.3 days in the control group respectively, there was also significant difference (P<0.01). The average time for the platelet transfusion was 2.2 in the test group, 4.1 in the control group, and there was significantly different (P<0.01). The average number of megakaryocytes was 12.2 in the test group, 4.8 in the control group on 30th day after the transplantation,and there was significant difference(P<0.01). The main side effects of rhIL-11 were nausea, vomit, debility, headache, dizzy and pain of injection site, and the degree was all Iapproximately II grade.
CONCLUSION
rhIL-11 has definite recuperative effect on the recovery of the platelet after PBSCT. There is little side effect, and it can be accepted.
Adolescent
;
Adult
;
Female
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Interleukin-11
;
genetics
;
therapeutic use
;
Leukemia
;
blood
;
surgery
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
blood
;
surgery
;
Leukemia, Myeloid, Acute
;
blood
;
surgery
;
Male
;
Middle Aged
;
Platelet Count
;
Recombinant Proteins
;
therapeutic use
;
Thrombocytopenia
;
drug therapy
;
Treatment Outcome
10.Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis.
A-Xia SONG ; Dong-Lin YANG ; Jia-Lin WEI ; Zhang-Song YAN ; Mei WANG ; Er-Lie JIANG ; Yong HUANG ; Qing-Guo LIU ; Qiao-Ling MA ; Wei-Hua ZHAI ; Rong-Li ZHANG ; Si-Zhou FENG ; Ming-Zhe HAN
Journal of Experimental Hematology 2010;18(1):161-166
This study was purposed to evaluate the outcome of patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in complete remission, and to study the prognostic factors. 75 cases of AML in complete remission receiving allo-HSCT from January 2000 to December 2007 were retrospectively analyzed. Major end points of study included overall survival (OS), disease free survival (DFS), relapse rate and transplantation related mortality (TRM). The results showed that 3-year OS and DFS of the study population reached to 58.4% and 53.9% respectively, and the relapse rate and TRM leaded to 16.9% and 29.9% respectively. Incidence of acute GVHD was 59.6%, with 18.7% II-IV aGVHD. Different prognosis was observed between HSCT recipients of alternative donor and HLA-matched related donor (MRD) (3-year DFS was 34.3% vs 60.0%, p = 0.019), between patients of refractory leukemia and the control (3-year DFS was 35.7% vs 58.2%, p = 0.048), between recipients with and without severe aGVHD (3-year DFS was 35.7% vs 54.4%, p = 0.059). Further analysis revealed significantly high TRM in recipients receiving allo-HSCT of alternative donor (p = 0.033) and high rate of severe aGVHD (p = 0.010). Multivariate analysis revealed three negative prognostic factors: donor availability (alternative vs MRD) (p = 0.049, RR = 2.09, 95%CI 1.01 - 4.36), refractory leukemia (p = 0.038, RR = 2.33, 95%CI 1.05 - 5.20) and severe aGVHD (p = 0.040, RR = 2.33, 95%CI 1.04 - 5.20). It is concluded that allo-HSCT is a choice for the AML case at complete remission and TRM is the major cause of the transplantation failure. Donor availability, refractory leukemia and severe aGVHD are confirmed as risk factors of poor prognosis for allo-HSCT patients with AML in CR.
Adolescent
;
Adult
;
Child
;
Child, Preschool
;
Female
;
Graft vs Host Disease
;
etiology
;
Hematopoietic Stem Cell Transplantation
;
adverse effects
;
methods
;
Humans
;
Leukemia, Myeloid, Acute
;
mortality
;
surgery
;
Male
;
Middle Aged
;
Prognosis
;
Recurrence
;
Risk Factors
;
Treatment Outcome
;
Young Adult